Gyre Therapeutics, Inc. (GYRE) Stock Price & Analysis
Gyre Therapeutics, Inc. (GYRE) closed at USD 6.4 on Thursday, October 15, 2026, down 1.08% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 6.47; the Oct 15, 2026 session ranged USD 6.4–6.65 on volume of 108,762 shares. Market capitalization is $678.62M, with a 52-week range of USD 5.44–9.42 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GYRE.md
Key facts (GYRE)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (3 analysts), mean target USD 18.67 (range 18–20).
- Total return with dividends: 1Y -26.8% vs S&P 500 +18.1%; 5Y -34.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.12, revenue estimate $28.4M.
Analysts (GYRE)
Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 18.67 (low 18, high 20).
Total return (dividends reinvested) (GYRE)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -26.8% | -34.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -26.9% | -8.1% |
| Volatility (annualized) | 55.1% | 103.0% |
| Max drawdown | -36.5% (Mar 2026→Jun 2026) | -91.0% (Oct 2021→May 2022) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 6.4 |
|---|---|
| Change | ▼ 1.08% (down) |
| Previous Close | USD 6.47 |
| Open | USD 6.51 |
| Day Range | USD 6.4 – 6.65 |
| 52-Week Range | USD 5.44 – 9.42 |
| Volume | 108,762 shares |
| Market Cap | $678.62M |
| Exchange | NCM |
Technical Analysis (GYRE)
Nexqual's technical model rates GYRE "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.31 (neutral) |
| vs SMA50 | Below (USD 6.89) |
| MACD | -0.08 (negative) |
Analyst Ratings (GYRE)
Wall Street analysts rate GYRE "Buy" based on 3 analysts, with a mean price target of USD 18.67 (range USD 18–20), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 18.67 |
| High Target | USD 20 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (GYRE)
| Next Earnings Date | 2026-11-05 |
|---|---|
| Revenue Estimate | $28.40M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.12 vs est -0.06 ▼ miss |
| 2026-03-31 | USD -0.1 vs est -0.07 ▼ miss |
| 2025-12-31 | USD 0.05 vs est 0.01 ▲ beat |
| 2025-09-30 | USD 0.03 vs est -0.02 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (GYRE)
| Total Revenue | $109.82M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -2.10% |
| Gross Margin | +93.80% |
| Operating Margin | -47.62% |
| Profit Margin | -19.33% |
| ROE | -17.44% |
| Debt / Equity | 0.02 |
| Current Ratio | 4.26 |
| Total Cash | $74.80M |
| Total Debt | $3.42M |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (GYRE)
Nexqual rates Gyre Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 94%, operating -48% |
| Balance Sheet | Strong — $75M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$5M (TTM) |
| Efficiency | Critical — ROE -17%, ROA -5.4% |
Ownership (GYRE)
| Insider Ownership | +74.40% |
|---|---|
| Institutional Ownership | +8.24% |
| Shares Outstanding | 106.03M |
| Float | 35.94M |
| Short % of Float | +6.45% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (GYRE)
Gyre Therapeutics, Inc. is led by Ying Luo (age 60), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| CEO, President & Director | Ying Luo (age 60) |
|---|---|
| Chief Financial Officer | Thomas W. Eastling (age 66) |
| Chief Operating Officer | Weiguo Ye (age 47) |
| Chief Scientific Officer & Director | Yue Xiong |
| Senior Vice President of Corporate Development | Seth Goldblum |
Major Backers & Investors (GYRE)
Notable institutional backers of Gyre Therapeutics, Inc. include HSG Holding Ltd, Octagon Capital Advisors LP, Fidelity, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HSG Holding Ltd | 3.36% |
| Octagon Capital Advisors LP | 0.86% |
| Fidelity | 0.34% |
| Charles Schwab Investment Management, Inc. | 0.17% |
| SBI Securities Co., Ltd. | 0.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.74% |
| BlackRock | 1.35% |
| Geode Capital | 0.48% |
| State Street | 0.22% |
| Northern Trust | 0.15% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt